Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease

European Journal of Medicinal Chemistry

Volumn 125, Issue , 2017, Pages 853-864

  Joubert, Jacques ^a   Foka, Germaine B ^a   Repsold, Benjamin P ^b   Oliver, Douglas W ^b   Kapp, Erika ^a   Malan, Sarel F ^a  

^a UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Alzheimer's disease; Cholinesterase; Coumarin; Donepezil; MAO B; Molecular modeling

Indexed keywords

4 METHYL 2 OXO 7 [2 (BENZYLPIPERIDIN 1 YL)ETHOXY] 2H CHROMENE 3 CARBONITRILE; 7 (BENZYLOXY) 3 CHLORO 4 METHYL 2H CHROMEN 2 ONE; CHOLINESTERASE INHIBITOR; COUMARIN DERIVATIVE; DONEPEZIL; MONOAMINE OXIDASE INHIBITOR; UNCLASSIFIED DRUG; AMINE OXIDASE (FLAVIN CONTAINING); AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; BENZYL DERIVATIVE; PEPTIDE FRAGMENT; PIPERIDINE DERIVATIVE; PROTEIN BINDING;

ALZHEIMER DISEASE; ARTICLE; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; IC50; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION; ANIMAL; BINDING SITE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; PROTEIN AGGREGATION, PATHOLOGICAL; SYNTHESIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BENZYL COMPOUNDS; BINDING SITES; CHOLINESTERASE INHIBITORS; COUMARINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PEPTIDE FRAGMENTS; PIPERIDINES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84992028376     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.09.041     Document Type: Article

References (63)

1. [1] Goedert, M., Spillantini, M., A century of Alzheimer's disease. Science 314 (2006), 777–781.
2. [2] Cummings, J., The dementias: diagnosis, treatment and Research. third ed. Arch. Neurol., 61, 2004, 1623.
3. [3] Grundke-Iqbal, I., Iqbal, K., Tung, Y., Quinlan, M., Wisniewski, H., Binder, L., Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. 83 (1986), 4913–4917.
4. [4] Castro, A., Martinez, A., Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. CPD 12 (2006), 4377–4387.
5. [5] Gella, A., Durany, N., Oxidative stress in Alzheimer disease. Cell Adhesion Migr. 3 (2009), 88–93.
6. [6] Coyle, J., Puttfarcken, P., Oxidative stress, glutamate, and neurodegenerative disorders. Science 262 (1993), 689–695.
7. [7] Talesa, V., Acetylcholinesterase in Alzheimer's disease. Mech. Ageing Dev. 122 (2001), 1961–1969.
8. [8] Birks, J., Harvey, R., Donepezil for dementia due to Alzheimer's disease. No. 1 Cochrane Database Syst. Rev., 2006, CD001190.
9. [9] Loy, C., Schneider, L., Galantamine for Alzheimer's disease. No. 4 Cochrane Database Syst. Rev., 2004, CD001747.
10. [10] Birks, J., Grimley, E.J., Iakovidou, V., Rivastigmine for Alzheimer's disease. No. 4 Cochrane Database Syst. Rev., 2000, CD001191.
11. [11] Greig, N., Utsuki, T., Ingram, D., Wang, Y., Pepeu, G., Scali, C., et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer B-amyloid peptide in rodent. Proc. Natl. Acad. Sci. 102 (2005), 17213–17218.
12. [12] Giacobini, E., Cholinergic function and Alzheimer's disease. Int. J. Geriat Psychiatry 18 (2003), S1–S5.
13. [13] Garcia-Alloza, M., Gil-Bea, F., Diez-Ariza, M., Chen, C., Francis, P., Lasheras, B., et al. Cholinergic–serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 43 (2005), 442–449.
14. [14] Terry, A., Buccafusco, J., Wilson, C., Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav. Brain Res. 195 (2008), 30–38.
15. [15] Dringenberg, H., Alzheimer's disease: more than a ‘cholinergic disorder’ — evidence that cholinergic–monoaminergic interactions contribute to EEG slowing and dementia. Behav. Brain Res. 115 (2000), 235–249.
16. [16] Riederer, P., Youdim, M., Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian patients treated with l-deprenyl. J. Neurochem. 46 (1986), 1359–1365.
17. [17] Kristal, S., Conway, D., Brown, M., Jain, C., Ulluci, A., Li, W., Burke, W., Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic. Biol. Med. 30 (2001), 924–931.
18. [18] Mitoma, J., Ito, A., Mitochondrial targeting signal of rat liver monoamine oxidase B is located at its carboxy terminus. J. Biochem. 111 (1992), 20–24.
19. [19] Greenawalt, J., An appraisal of the use of monoamine oxidase as an enzyme marker for the outer membrane of rat liver mitochondria. J. Cell Biol. 46 (1970), 173–179.
20. [20] Johnston, J., Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17 (1968), 1285–1297.
21. [21] Youdim, M., Edmondson, D., Tipton, K., The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 7 (2006), 295–309.
22. [22] Pizzinat, N., Copin, N., Vindis, C., Parini, A., Cambon, C., Reactive oxygen species production by monoamine oxidases in intact cells. Naunyn-Schmiedeberg's Archives Pharmacol. 359 (1999), 428–431.
23. [23] Danielczyk, W., Streifler, M., Konradi, C., Riederer, P., Moll, G., Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia. Acta Psychiatr. Scand. 78 (1988), 730–736.
24. [24] Cai, Z., Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review). Mol. Med. Rep., 5, 2014.
25. [25] Vishnu Nayak, B., Ciftci-Yabanoglu, S., Jadav, S., Jagrat, M., Sinha, B., Ucar, G., et al. Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives. Eur. J. Med. Chem. 69 (2013), 762–767.
26. [26] Filip, B., Kolibas, E., Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and slovak senile dementia of alzheimer type study group. J. Psychiatry Neurosci. 24 (1999), 234–243.
27. [27] Joubert, J., Petzer, J., Prins, L., Repsold, B., Malan, S., Multifunctional enzyme inhibition for neuroprotection: A focus on MAO, NOS and AChE inhibitors. In Drug Design and Discovery in Alzheimer's Disease. Bentham Books., 2014, 291–365.
28. [28] Cavalli, A., Bolognesi, M., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., et al. Multi-target-Directed ligands to combat neurodegenerative diseases. J. Med. Chem. 51 (2008), 347–372.
29. [29] Youdim, M., Buccafusco, J., Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 26 (2005), 27–35.
30. [30] Brühlmann, C., Ooms, F., Carrupt, P., Testa, B., Catto, M., Leonetti, F., et al. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J. Med. Chem. 44 (2001), 3195–3198.
31. [31] Sterling, J., Herzig, Y., Goren, T., Finkelstein, N., Lerner, D., Goldenberg, W., et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and Phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem. 45 (2002), 5260–5279.
32. [32] Pisani, L., Catto, M., Leonetti, F., Nicolotti, O., Stefanachi, A., Campagna, F., et al. Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases. Curr. Med. Chem. 18 (2011), 4568–4587.
33. [33] Bolea, I., Juárez-Jiménez, J., de los Rı́os, C., Chioua, M., Pouplana, R., Luque, F., et al. Synthesis, biological evaluation, and molecular modeling of donepezil and N -[(5-(benzyloxy)-1-methyl-1 H -indol-2-yl)methyl]- N -methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem. 54 (2011), 8251–8270.
34. [34] Samadi, A., de los Ríos, C., Bolea, I., Chioua, M., Iriepa, I., Moraleda, I., et al. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. Eur. J. Med. Chem. 52 (2012), 251–262.
35. [35] Yanez, M., Vina, D., Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of alzheimer disease. CTMC 13 (2013), 1692–1706.
36. [36] Bautista-Aguilera, O., Samadi, A., Chioua, M., Nikolic, K., Filipic, S., Agbaba, D., et al. N -methyl- N -((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1 H -indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor. J. Med. Chem. 57 (2014), 10455–10463.
37. [37] Wang, L., Esteban, G., Ojima, M., Bautista-Aguilera, O., Inokuchi, T., Moraleda, I., et al. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease. Eur. J. Med. Chem. 80 (2014), 543–561.
38. [38] Farina, R., Pisani, L., Catto, M., Nicolotti, O., Gadaleta, D., Denora, N., et al. Structure-based design and optimization of multitarget-directed 2 H -Chromen-2-one derivatives as potent inhibitors of monoamine oxidase B and cholinesterases. J. Med. Chem. 58 (2015), 5561–5578.
39. [39] Xie, S., Lan, J., Wang, X., Wang, Z., Jiang, N., Li, F., et al. Design, synthesis and biological evaluation of novel donepezil–coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease. Bioorg. Med. Chem. 24 (2016), 1528–1539.
40. [40] Patil, P., Bari, S., Firke, S., Deshmukh, P., Donda, S., Patil, D., A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease. Bioorg. Med. Chem. 21 (2013), 2434–2450.
41. [41] Gnerre, C., Catto, M., Leonetti, F., Weber, P., Carrupt, P., Altomare, C., et al. Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J. Med. Chem. 43 (2000), 4747–4758.
42. [42] Pisani, L., Muncipinto, G., Miscioscia, T., Nicolotti, O., Leonetti, F., Catto, M., et al. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor. J. Med. Chem. 52 (2009), 6685–6706.
43. [43] Binda, C., Wang, J., Pisani, L., Caccia, C., Carotti, A., Salvati, P., et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J. Med. Chem. 50 (2007), 5848–5852.
44. [44] Inestrosa, N., Alvarez, A., Pérez, C., Moreno, R., Vicente, M., Linker, C., et al. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 16 (1996), 881–891.
45. [45] De Ferrari, G., Canales, M., Shin, I., Weiner, L., Silman, I., Inestrosa, N., A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry 40 (2001), 10447–10457.
46. [46] Rees, T., Berson, A., Sklan, E., Younkin, L., Younkin, S., Brimijoin, S., et al. Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. CAR 2 (2005), 291–300.
47. [47] Dinamarca, M., Sagal, J., Quintanilla, R., Godoy, J., Arrázola, M., Inestrosa, N., Amyloid-β-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Aβ peptide. Implications for the pathogenesis of Alzheimer's disease. Mol. Neurodegener., 5, 2010, 4.
48. [48] Novaroli, L., Reist, M., Favre, E., Carotti, A., Catto, M., Carrupt, P., Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. Bioorg. Med. Chem. 13 (2005), 6212–6217.
49. [49] Tavari, M., Malan, S., Joubert, J., Design, synthesis, biological evaluation and docking studies of sulfonyl isatin derivatives as monoamine oxidase and caspase-3 inhibitors. Med. Chem. Commun., 2016, 10.1039/c6md00228e.
50. [50] Ellman, G., Courtney, K., Andres, V., Featherstone, R., A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7 (1961), 88–95.
51. [51] Meng, F., Mao, F., Shan, W., Qin, F., Huang, L., Li, X., Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents. Bioorg. Med. Chem. Lett. 22 (2012), 4462–4466.
52. [52] Sugimoto, H., Ogura, H., Arai, Y., Iimura, Y., Yamanishi, Y., Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn. J. Pharmacol. 89 (2002), 7–20.
53. [53] Son, S., Ma, J., Kondou, Y., Yoshimura, M., Yamashita, E., Tsukihara, T., Proc. Natl. Acad. Sci. 105 (2008), 5739–5744.
54. [54] Kryger, G., Silman, I., Sussman, J., Structure of acetylcholinesterase complexed with E2020 (Aricept®): implications for the design of new anti-Alzheimer drugs. Structure 7 (1999), 297–307.
55. [55] Molecular Operating Environment (MOE), Version 2015.10. http//www.chemcomp.com.
56. [56] Arnold, K., Bordoli, L., Kopp, J., Schwede, T., The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22 (2005), 195–201.
57. [57] Kiefer, F., Arnold, K., Kunzli, M., Bordoli, L., Schwede, T., The SWISS-MODEL Repository and associated resources. Nucleic Acids Res. 37 (2009), D387–D392.
58. [58] Trott Olson, A., AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31 (2009), 455–461.
59. [59] Bajda, M., Więckowska, A., Hebda, M., Guzior, N., Sotriffer, C., Malawska, B., Structure-based search for new inhibitors of cholinesterases. IJMS 14 (2013), 5608–5632.
60. [60] Venneri, A., McGeown, W., Shanks, M., Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimers disease. NeuroReport 16 (2005), 107–110.
61. [61] Giacobini, E., Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol. Res. 50 (2004), 433–440.
62. [62] Binda, C., Li, M., Hubalek, F., Restelli, N., Edmondson, D., Mattevi, A., Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl. Acad. Sci. 100 (2003), 9750–9755.
63. [63] Boström, J., Greenwood, J., Gottfries, J., Assessing the performance of OMEGA with respect to retrieving bioactive conformations. J. Mol. Graph. Model. 21 (2003), 449–462.